About The Conference

Why to attend?

With individuals from around the world zeroed in on finding out with regards to Breast Cancer and therapy and to tackle main points of interest confronting patients all through the continuum of the breast malignancy venture; this is your best chance to arrive at the biggest collection of members from the Breast Cancer people group. Direct introductions, convey data, meet with current and expected researchers, make a sprinkle with new disclosures in the breast cancer treatment and analysis, and get name acknowledgment at this 2-day occasion. Incredibly famous speakers, the latest procedures, advancements, and the freshest updates in breast malignant growth, lady brain science, ladies problems are signs of this gathering.

Target Audience

• Radiologist

• Radiation Oncologist

• Radiation Therapist

• Medical Oncologist

• Breast Care Nurse

• Surgeon

• Reconstructive (plastic) Surgeon

• Lymphoedema Therapist

• Breast Cancer Surgeons, pathologists

• Nurse Practitioners/Nurses

• Healthcare Faculty

• Medical Colleges

• Healthcare Associations and Societies

• Business Entrepreneurs

• Training Institutes

• Manufacturing Medical Devices Companies

Sessions and Tracks

Track 1: Advances in Breast Cancer Diagnosis

Explore the latest diagnostic innovations including AI-assisted imaging, liquid biopsies, and molecular profiling. This track covers early detection strategies, screening protocols, and biomarkers that enhance diagnostic accuracy and help reduce false positives and overdiagnosis. Discussions will also include personalized diagnostics for high-risk populations and integration of precision imaging in clinical practice.

Track 2: Innovations in Breast Cancer Treatment

This track focuses on the latest therapeutic strategies including targeted therapies, immunotherapies, and antibody-drug conjugates. Experts will discuss treatment customization based on tumor genetics, emerging clinical trial outcomes, and strategies to minimize toxicity. It’s a comprehensive look at how innovation is reshaping therapeutic paradigms in breast cancer care.

Track 3: Triple-Negative Breast Cancer (TNBC)

Dive into the complexities of TNBC, a particularly aggressive subtype. The track will highlight advancements in molecular characterization, novel treatment options like PARP inhibitors and checkpoint inhibitors, and current research aimed at understanding its heterogeneity. Multidisciplinary approaches to improve patient outcomes will be emphasized.

Track 4: Hormone Receptor-Positive Breast Cancer

This track examines updates in endocrine therapies, resistance mechanisms, and combination strategies for ER/PR-positive breast cancer. Learn about next-generation SERDs, CDK4/6 inhibitors, and how genomic profiling is refining hormone-driven treatment planning. Patient management and long-term survivorship challenges will also be covered.

Track 5: HER2-Positive Breast Cancer

Focused on HER2-targeted therapies such as trastuzumab, pertuzumab, and novel agents like tucatinib, this track dives into treatment evolution and resistance challenges. Attendees will explore dual HER2 blockade, ADCs, and the role of HER2-low classification in guiding future treatment landscapes.

Track 6: Breast Cancer in Young Women

Addressing the unique challenges faced by younger patients, this track highlights fertility preservation, psychosocial aspects, aggressive tumor biology, and tailored treatment approaches. Discussions will also cover hereditary syndromes, genetic counseling, and long-term survivorship considerations for this patient population.

Track 7: Breast Cancer and Pregnancy

This track delves into the complexities of diagnosing and managing breast cancer during pregnancy. Topics include safe imaging practices, treatment timing, maternal-fetal outcomes, and ethical considerations. It’s an essential session for both oncologists and obstetric care providers.

Track 8: Genetic Predisposition and BRCA Mutations

Explore hereditary breast cancer syndromes with a focus on BRCA1/2 and beyond. This track covers genetic screening protocols, risk-reducing strategies, implications for family members, and targeted therapies for mutation carriers. Genetic counseling and population-specific mutation profiles will also be discussed.

Track 9: Breast Cancer Imaging and Radiology

From mammography to MRI and contrast-enhanced imaging, this track highlights cutting-edge radiological techniques. Explore the role of AI, radiogenomics, and real-time image-guided biopsy procedures. A must-attend for radiologists and technologists involved in breast cancer detection and monitoring.

Track 10: Surgical Oncology in Breast Cancer

This track offers insights into modern surgical techniques such as nipple-sparing mastectomy, oncoplastic surgery, and sentinel lymph node biopsy. It will also cover patient-centric decisions around breast conservation versus mastectomy, and advancements in minimally invasive procedures.

Track 11: Radiation Therapy in Breast Cancer

Explore the evolving role of radiation oncology including hypofractionation, proton therapy, and intraoperative radiotherapy. Sessions will focus on reducing toxicity, improving targeting accuracy, and optimizing treatment timing in multidisciplinary care models.

Track 12: Breast Reconstruction and Cosmetic Outcomes

This track discusses innovations in reconstructive techniques post-mastectomy, including autologous tissue reconstruction, implant-based options, and 3D surgical planning. Emphasis is placed on achieving oncologic safety alongside aesthetic and psychological recovery.

Track 13: Psychosocial Support and Survivorship

This session highlights mental health support, survivorship planning, and rehabilitation. Attendees will learn about managing fatigue, anxiety, body image issues, and long-term treatment side effects. Holistic care approaches and integrative oncology practices are also discussed.

Track 14: Breast Cancer in Men

Often overlooked, male breast cancer poses unique diagnostic and therapeutic challenges. This track addresses epidemiology, clinical presentation, and gender-specific treatment protocols while raising awareness about early detection and stigma reduction.

Track 15: Breast Cancer Prevention and Lifestyle

Focusing on modifiable risk factors, this track explores lifestyle interventions, dietary influence, physical activity, and chemoprevention strategies. Public health initiatives and education campaigns aimed at prevention will be featured.

Track 16: Artificial Intelligence & Big Data in Breast Oncology

Discover how AI, machine learning, and big data are transforming breast cancer research and patient care. This track will showcase predictive analytics, decision-support tools, and AI-integrated imaging diagnostics, offering a glimpse into the future of personalized oncology.

Market Analysis

The global breast cancer market is poised for significant growth leading up to the 2026 Breast Cancer Summit, reflecting advancements in therapeutics, diagnostics, and patient-centered care. Valued at approximately USD 38.06 billion in 2025, the market is projected to reach USD 89.01 billion by 2034, driven by a robust CAGR of 9.90% . This expansion is fueled by the increasing prevalence of breast cancer, particularly hormone receptor-positive and HER2-positive subtypes, which account for a substantial portion of cases. Innovations in targeted therapies, such as CDK4/6 inhibitors and HER2-directed treatments, are enhancing patient outcomes and reshaping treatment paradigms. Notably, Roche's development of giredestrant, an oral selective estrogen receptor degrader (SERD), underscores the industry's focus on novel therapeutics, with the potential to tap into a market exceeding USD 12 billion annually if clinical trials prove successful .

Concurrently, the breast cancer diagnostics sector is experiencing growth, propelled by government initiatives aimed at early detection and improved screening programs. Technological advancements, including AI-driven imaging and genomic testing, are facilitating more accurate diagnoses and personalized treatment strategies . In the Asia-Pacific region, countries like India are witnessing a surge in breast cancer cases, prompting increased investment in healthcare infrastructure and awareness campaigns . Furthermore, the adaptive fashion market, catering to breast cancer survivors, is expanding, with projections indicating growth from USD 15.8 billion in 2024 to USD 29.8 billion by 2031 . This holistic approach to patient care, encompassing medical treatment and quality of life considerations, will be a focal point at the 2026 Breast Cancer Summit, highlighting the importance of integrated strategies in combating breast cancer globally.